T-cell acute lymphoblastic leukemia.

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• T-cell acute lymphoblastic leukemia (T-ALL) is distinct from B-cell acute lymphoblastic leukemia (B-ALL) in disease kinetics and response to therapy.
• Minimal residual disease (MRD) is the primary prognostic factor in T-ALL, overshadowing other clinical and genetic markers.
• Recent genomic studies reveal targetable pathways in T-ALL, including Notch, Jak/Stat, PI3K/Akt/mTOR, and MAPK.

Purpose of the Study:

• To summarize current understanding of T-ALL biology and treatment.
• To highlight advances in T-ALL genomics and targeted therapies.
• To address challenges in managing relapsed T-ALL and improving patient outcomes.

Main Methods:

• Review of contemporary chemotherapy regimens for T-ALL.
• Analysis of prognostic factors, emphasizing the role of MRD.
• Integration of modern genomic findings to identify therapeutic targets.

Main Results:

• Contemporary chemotherapy yields an approximately 85% 5-year event-free survival for de novo T-ALL.
• Relapsed T-ALL has poor outcomes, with less than 25% event-free and overall survival.
• Genomic insights have identified several key molecular pathways for targeted therapy.

Conclusions:

• T-ALL treatment outcomes have improved but relapse remains a significant challenge.
• Future strategies should focus on intensifying therapy for high-risk patients and developing novel treatments for relapsed disease.
• Targeting identified molecular pathways holds promise for improving T-ALL management.